Study S001584
Liraglutide Effect and Action in Diabetes (LEAD-1): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride Versus Glimepiride Monotherapy Versus Glimepiride and Rosiglitazone Combination Therapy in Subjects With Type 2 Diabetes.
Registration
Registered primary outcomes
- HbA1c [after 26 weeks of treatment]
Linked records (15)
Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
| Record | Title | Year | Design | Identifiers | Link basis |
|---|---|---|---|---|---|
| R0023483 | Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Jensen TM, Diabetes care | 2015 | Systematic review | PMID 25504028DOI | registry reference RESULT:25504028 |
| R0026607 | Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. Fonseca VA, Journal of diabetes and its complications | 2014 | Randomized trial | PMID 24561125DOI | cites ClinicalTrials.gov:NCT00318422; registry reference DERIVED:24561125 |
| R0016483 | Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Niswender K, Diabetes, obesity & metabolism | 2013 | Randomized trial | PMID 22862847DOI | registry reference RESULT:22862847 |
| R0023531 | Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%. King AB, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists | 2013 | Other | PMID 23186975DOI | registry reference RESULT:23186975 |
| R0020069 | A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Alves C, Diabetes research and clinical practice | 2012 | Systematic review | PMID 23010561DOI | registry reference RESULT:23010561 |
| R0022006 | Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Zinman B, Diabetes, obesity & metabolism | 2012 | Systematic review | PMID 21883806DOI | registry reference RESULT:21883806 |
| R0017232 | Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Buse JB, The Journal of clinical endocrinology and metabolism | 2011 | Other trial | PMID 21450987DOI | registry reference RESULT:21450987 |
| R0020188 | GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. Hegedüs L, The Journal of clinical endocrinology and metabolism | 2011 | Preclinical | PMID 21209033DOI | cites ClinicalTrials.gov:NCT00318422; registry reference RESULT:21209033 |
| R0024125 | Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies. Bode BW, The American journal of geriatric pharmacotherapy | 2011 | Randomized trial | PMID 22055210DOI | registry reference RESULT:22055210 |
| R0025876 | Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program. Henry RR, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists | 2011 | Systematic review | PMID 22193143DOI | registry reference RESULT:22193143 |
| R0022254 | Insights from the Liraglutide Clinical Development Program--the Liraglutide Effect and Action in Diabetes (LEAD) studies. McGill JB, Postgraduate medicine | 2009 | Randomized trial | PMID 19491536DOI | registry reference RESULT:19491536 |
| R0022352 | The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Blonde L, Diabetes, obesity & metabolism | 2009 | Other trial | PMID 19878259DOI | registry reference RESULT:19878259 |
| R0026002 | Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. Sullivan SD, Cardiovascular diabetology | 2009 | Nonrandomized study | PMID 19245711DOI | cites ClinicalTrials.gov:NCT00318422; registry reference RESULT:19245711 |
| R0026073 | Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Marre M, Diabetic medicine : a journal of the British Diabetic Association | 2009 | Randomized trial | PMID 19317822DOI | registry reference RESULT:19317822 |
| R0027548 | Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Nauck M, Postgraduate medicine | 2009 | Randomized trial | PMID 19491535DOI | cites ClinicalTrials.gov:NCT00318422; registry reference RESULT:19491535 |